APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Spinal Muscular Atrophy (SMA)

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Drugs for Spinal Muscular Atrophy (SMA) Industry Growth and Trends Forecast to 2032

28 December 202572 pages

Choose your research edition.

Industry ResearchDrugs for Spinal Muscular Atrophy (SMA) Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Spinal Muscular Atrophy (SMA) Industry Growth and Trends Forecast to 203272 pages · $3,450 USDMarket StructureGlobal Drugs for Spinal Muscular Atrophy (SMA) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032175 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Spinal Muscular Atrophy (SMA) Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Spinal Muscular Atrophy (SMA) Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Drugs for Spinal Muscular Atrophy (SMA) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Drugs for Spinal Muscular Atrophy (SMA) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Drugs for Spinal Muscular Atrophy (SMA) is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs for Spinal Muscular Atrophy (SMA) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Drugs for Spinal Muscular Atrophy (SMA) include Novartis, Ionis Pharmaceuticals, Genentech and Biogen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Drugs for Spinal Muscular Atrophy (SMA) market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Drugs for Spinal Muscular Atrophy (SMA) market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Drugs for Spinal Muscular Atrophy (SMA) market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Drugs for Spinal Muscular Atrophy (SMA).

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Drugs for Spinal Muscular Atrophy (SMA) market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Drugs for Spinal Muscular Atrophy (SMA) Market by Company

Novartis

Ionis Pharmaceuticals

Genentech

Biogen

Drugs for Spinal Muscular Atrophy (SMA) Segment by Type

Oral Drugs

Injections

Drugs for Spinal Muscular Atrophy (SMA) Segment by Application

Hospital

Clinic

Other

Drugs for Spinal Muscular Atrophy (SMA) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Spinal Muscular Atrophy (SMA) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Spinal Muscular Atrophy (SMA) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Spinal Muscular Atrophy (SMA).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Drugs for Spinal Muscular Atrophy (SMA) manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Drugs for Spinal Muscular Atrophy (SMA) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Oral Drugs Table 2. Major Company of Injections Table 3. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021-2026) & (K Units) Table 5. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Volume by Type (2021-2026) Table 6. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021-2026) & (US$ Million) Table 7. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Value by Type (2021-2026) Table 8. Global Drugs for Spinal Muscular Atrophy (SMA) Price by Type (2021-2026) & (US$/Unit) Table 9. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2027-2032) & (K Units) Table 10. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Volume by Type (2027-2032) Table 11. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2027-2032) & (US$ Million) Table 12. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Value by Type (2027-2032) Table 13. Global Drugs for Spinal Muscular Atrophy (SMA) Price by Type (2027-2032) & (US$/Unit) Table 14. North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021-2026) & (K Units) Table 15. North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021-2026) & (K Units) Table 17. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021-2026) & (K Units) Table 21. Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021-2026) & (US$ Million) Table 24. Drugs for Spinal Muscular Atrophy (SMA) Industry Trends Table 25. Drugs for Spinal Muscular Atrophy (SMA) Industry Drivers Table 26. Drugs for Spinal Muscular Atrophy (SMA) Industry Opportunities and Challenges Table 27. Drugs for Spinal Muscular Atrophy (SMA) Industry Restraints Table 28. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Company (2021-2026) Table 30. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Company (2021-2026) & (K Units) Table 31. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Share by Company (2021-2026) Table 32. Global Drugs for Spinal Muscular Atrophy (SMA) Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Drugs for Spinal Muscular Atrophy (SMA) Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Drugs for Spinal Muscular Atrophy (SMA) Major Company Production Sites and Headquarters Table 35. Global Drugs for Spinal Muscular Atrophy (SMA) Company, Product Type & Application Table 36. Global Drugs for Spinal Muscular Atrophy (SMA) Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Drugs for Spinal Muscular Atrophy (SMA) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Drugs for Spinal Muscular Atrophy (SMA) Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (2021-2026) & (K Units) Table 41. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Volume by Region (2021-2026) Table 42. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (2021-2026) & (US$ Million) Table 43. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Value by Region (2021-2026) Table 44. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (2027-2032) & (K Units) Table 46. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Volume by Region (2027-2032) Table 47. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (2027-2032) & (US$ Million) Table 48. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Value by Region (2027-2032) Table 49. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021-2026) & (K Units) Table 52. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Volume by Application (2021-2026) Table 53. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021-2026) & (US$ Million) Table 54. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Value by Application (2021-2026) Table 55. Global Drugs for Spinal Muscular Atrophy (SMA) Price by Application (2021-2026) & (US$/Unit) Table 56. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2027-2032) & (K Units) Table 57. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Volume by Application (2027-2032) Table 58. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2027-2032) & (US$ Million) Table 59. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Value by Application (2027-2032) Table 60. Global Drugs for Spinal Muscular Atrophy (SMA) Price by Application (2027-2032) & (US$/Unit) Table 61. North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021-2026) & (K Units) Table 62. North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021-2026) & (K Units) Table 64. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021-2026) & (K Units) Table 68. Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021-2026) & (US$ Million) Table 71. Novartis Company Information Table 72. Novartis Business Overview Table 73. Novartis Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Novartis Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio Table 75. Novartis Recent Development Table 76. Ionis Pharmaceuticals Company Information Table 77. Ionis Pharmaceuticals Business Overview Table 78. Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio Table 80. Ionis Pharmaceuticals Recent Development Table 81. Genentech Company Information Table 82. Genentech Business Overview Table 83. Genentech Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Genentech Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio Table 85. Genentech Recent Development Table 86. Biogen Company Information Table 87. Biogen Business Overview Table 88. Biogen Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Biogen Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio Table 90. Biogen Recent Development Table 91. North America Drugs for Spinal Muscular Atrophy (SMA) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 92. North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021-2026) & (K Units) Table 93. North America Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2021-2026) Table 94. North America Drugs for Spinal Muscular Atrophy (SMA) Sales Forecast by Country (2027-2032) & (K Units) Table 95. North America Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share Forecast by Country (2027-2032) Table 96. North America Drugs for Spinal Muscular Atrophy (SMA) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 97. North America Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country (2021-2026) & (US$ Million) Table 98. North America Drugs for Spinal Muscular Atrophy (SMA) Market Share by Country (2021-2026) Table 99. North America Drugs for Spinal Muscular Atrophy (SMA) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 100. North America Drugs for Spinal Muscular Atrophy (SMA) Market Share Forecast by Country (2027-2032) Table 101. Europe Drugs for Spinal Muscular Atrophy (SMA) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 102. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021-2026) & (K Units) Table 103. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2021-2026) Table 104. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Forecast by Country (2027-2032) & (K Units) Table 105. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share Forecast by Country (2027-2032) Table 106. Europe Drugs for Spinal Muscular Atrophy (SMA) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 107. Europe Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country (2021-2026) & (US$ Million) Table 108. Europe Drugs for Spinal Muscular Atrophy (SMA) Market Share by Country (2021-2026) Table 109. Europe Drugs for Spinal Muscular Atrophy (SMA) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 110. Europe Drugs for Spinal Muscular Atrophy (SMA) Market Share Forecast by Country (2027-2032) Table 111. Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 112. Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021-2026) & (K Units) Table 113. Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2021-2026) Table 114. Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales Forecast by Country (2027-2032) & (K Units) Table 115. Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share Forecast by Country (2027-2032) Table 116. Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 117. Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country (2021-2026) & (US$ Million) Table 118. Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Market Share by Country (2021-2026) Table 119. Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 120. Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Market Share Forecast by Country (2027-2032) Table 121. Latin America Drugs for Spinal Muscular Atrophy (SMA) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 122. Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021-2026) & (K Units) Table 123. Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2021-2026) Table 124. Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales Forecast by Country (2027-2032) & (K Units) Table 125. Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share Forecast by Country (2027-2032) Table 126. Latin America Drugs for Spinal Muscular Atrophy (SMA) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 127. Latin America Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country (2021-2026) & (US$ Million) Table 128. Latin America Drugs for Spinal Muscular Atrophy (SMA) Market Share by Country (2021-2026) Table 129. Latin America Drugs for Spinal Muscular Atrophy (SMA) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 130. Latin America Drugs for Spinal Muscular Atrophy (SMA) Market Share Forecast by Country (2027-2032) Table 131. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 132. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021-2026) & (K Units) Table 133. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2021-2026) Table 134. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales Forecast by Country (2027-2032) & (K Units) Table 135. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share Forecast by Country (2027-2032) Table 136. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country (2021-2026) & (US$ Million) Table 138. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Market Share by Country (2021-2026) Table 139. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Market Share Forecast by Country (2027-2032) Table 141. Key Raw Materials Table 142. Raw Materials Key Suppliers Table 143. Drugs for Spinal Muscular Atrophy (SMA) Distributors List Table 144. Drugs for Spinal Muscular Atrophy (SMA) Customers List Table 145. Research Programs/Design for This Report Table 146. Authors List of This Report Table 147. Secondary Sources Table 148. Primary Sources List of Figures Figure 1. Drugs for Spinal Muscular Atrophy (SMA) Image Figure 2. Global Drugs for Spinal Muscular Atrophy (SMA) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Spinal Muscular Atrophy (SMA) Market Size (2021-2032) & (US$ Million) Figure 4. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (2021-2032) & (K Units) Figure 5. Oral Drugs Image Figure 6. Global Oral Drugs Sales YoY Growth (2021-2032) & (K Units) Figure 7. Injections Image Figure 8. Global Injections Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Drugs for Spinal Muscular Atrophy (SMA) Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Drugs for Spinal Muscular Atrophy (SMA) Market Share by Type 2025 VS 2032 Figure 11. North America Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Volume by Type in 2025 Figure 12. North America Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Value by Type in 2025 Figure 13. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Volume by Type in 2025 Figure 14. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Value by Type in 2025 Figure 17. Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Drugs for Spinal Muscular Atrophy (SMA) Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospital Image Figure 24. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 25. Clinic Image Figure 26. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 27. Other Image Figure 28. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global Drugs for Spinal Muscular Atrophy (SMA) Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Drugs for Spinal Muscular Atrophy (SMA) Market Share by Application 2025 VS 2032 Figure 31. North America Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Volume by Application in 2025 Figure 32. North America Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Value by Application in 2025 Figure 33. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Volume by Application in 2025 Figure 34. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Value by Application in 2025 Figure 37. Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share in Value by Application in 2025 Figure 41. North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America Drugs for Spinal Muscular Atrophy (SMA) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Drugs for Spinal Muscular Atrophy (SMA) Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Drugs for Spinal Muscular Atrophy (SMA) Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Drugs for Spinal Muscular Atrophy (SMA) Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Drugs for Spinal Muscular Atrophy (SMA) Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Drugs for Spinal Muscular Atrophy (SMA) Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Drugs
  • Injections
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Novartis
  • Ionis Pharmaceuticals
  • Genentech
  • Biogen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Drugs for Spinal Muscular Atrophy (SMA) Market by Type
  6. 1.3.1 Oral Drugs
  7. 1.3.2 Injections
  8. 1.4 Global Drugs for Spinal Muscular Atrophy (SMA) Market Size by Type
  9. 1.4.1 Global Drugs for Spinal Muscular Atrophy (SMA) Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Drugs for Spinal Muscular Atrophy (SMA) Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Drugs for Spinal Muscular Atrophy (SMA) Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Drugs for Spinal Muscular Atrophy (SMA) Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Drugs for Spinal Muscular Atrophy (SMA) Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Drugs for Spinal Muscular Atrophy (SMA) Industry Trends
  2. 2.2 Drugs for Spinal Muscular Atrophy (SMA) Industry Drivers
  3. 2.3 Drugs for Spinal Muscular Atrophy (SMA) Industry Opportunities and Challenges
  4. 2.4 Drugs for Spinal Muscular Atrophy (SMA) Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2026)
  2. 3.2 Global Top Players by Drugs for Spinal Muscular Atrophy (SMA) Sales (2021-2026)
  3. 3.3 Global Top Players by Drugs for Spinal Muscular Atrophy (SMA) Price (2021-2026)
  4. 3.4 Global Drugs for Spinal Muscular Atrophy (SMA) Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Drugs for Spinal Muscular Atrophy (SMA) Major Company Production Sites & Headquarters
  6. 3.6 Global Drugs for Spinal Muscular Atrophy (SMA) Company, Product Type & Application
  7. 3.7 Global Drugs for Spinal Muscular Atrophy (SMA) Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Drugs for Spinal Muscular Atrophy (SMA) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Drugs for Spinal Muscular Atrophy (SMA) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Drugs for Spinal Muscular Atrophy (SMA) Tier 1, Tier 2, and Tier 3
4 Drugs for Spinal Muscular Atrophy (SMA) Regional Status and Outlook
  1. 4.1 Global Drugs for Spinal Muscular Atrophy (SMA) Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Drugs for Spinal Muscular Atrophy (SMA) Historic Market Size by Region
  3. 4.2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Drugs for Spinal Muscular Atrophy (SMA) Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Drugs for Spinal Muscular Atrophy (SMA) Forecasted Market Size by Region
  7. 4.3.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Drugs for Spinal Muscular Atrophy (SMA) Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Drugs for Spinal Muscular Atrophy (SMA) by Application
  1. 5.1 Drugs for Spinal Muscular Atrophy (SMA) Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Drugs for Spinal Muscular Atrophy (SMA) Market Size by Application
  6. 5.2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Drugs for Spinal Muscular Atrophy (SMA) Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Drugs for Spinal Muscular Atrophy (SMA) Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Drugs for Spinal Muscular Atrophy (SMA) Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Drugs for Spinal Muscular Atrophy (SMA) Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Novartis
  2. 6.1.1 Novartis Company Information
  3. 6.1.2 Novartis Business Overview
  4. 6.1.3 Novartis Drugs for Spinal Muscular Atrophy (SMA) Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Novartis Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
  6. 6.1.5 Novartis Recent Developments
  7. 6.2 Ionis Pharmaceuticals
  8. 6.2.1 Ionis Pharmaceuticals Company Information
  9. 6.2.2 Ionis Pharmaceuticals Business Overview
  10. 6.2.3 Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
  12. 6.2.5 Ionis Pharmaceuticals Recent Developments
  13. 6.3 Genentech
  14. 6.3.1 Genentech Company Information
  15. 6.3.2 Genentech Business Overview
  16. 6.3.3 Genentech Drugs for Spinal Muscular Atrophy (SMA) Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Genentech Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
  18. 6.3.5 Genentech Recent Developments
  19. 6.4 Biogen
  20. 6.4.1 Biogen Company Information
  21. 6.4.2 Biogen Business Overview
  22. 6.4.3 Biogen Drugs for Spinal Muscular Atrophy (SMA) Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Biogen Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
  24. 6.4.5 Biogen Recent Developments
7 North America by Country
  1. 7.1 North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country
  2. 7.1.1 North America Drugs for Spinal Muscular Atrophy (SMA) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021-2026)
  4. 7.1.3 North America Drugs for Spinal Muscular Atrophy (SMA) Sales Forecast by Country (2027-2032)
  5. 7.2 North America Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country
  6. 7.2.1 North America Drugs for Spinal Muscular Atrophy (SMA) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country (2021-2026)
  8. 7.2.3 North America Drugs for Spinal Muscular Atrophy (SMA) Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Country
  2. 8.1.1 Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021-2026)
  4. 8.1.3 Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country
  6. 8.2.1 Europe Drugs for Spinal Muscular Atrophy (SMA) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country (2021-2026)
  8. 8.2.3 Europe Drugs for Spinal Muscular Atrophy (SMA) Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales by Country
  2. 9.1.1 Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country
  6. 9.2.1 Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country
  2. 10.1.1 South America Drugs for Spinal Muscular Atrophy (SMA) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021-2026)
  4. 10.1.3 South America Drugs for Spinal Muscular Atrophy (SMA) Sales Forecast by Country (2027-2032)
  5. 10.2 South America Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country
  6. 10.2.1 South America Drugs for Spinal Muscular Atrophy (SMA) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country (2021-2026)
  8. 10.2.3 South America Drugs for Spinal Muscular Atrophy (SMA) Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales by Country
  2. 11.1.1 Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country
  6. 11.2.1 Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Drugs for Spinal Muscular Atrophy (SMA) Value Chain Analysis
  2. 12.1.1 Drugs for Spinal Muscular Atrophy (SMA) Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Drugs for Spinal Muscular Atrophy (SMA) Production Mode & Process
  7. 12.2 Drugs for Spinal Muscular Atrophy (SMA) Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Drugs for Spinal Muscular Atrophy (SMA) Distributors
  10. 12.2.3 Drugs for Spinal Muscular Atrophy (SMA) Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst